CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
CPRX on Nasdaq
Shares outstanding
123,180,519
Price per share
$23.34
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
103,326,904
Total reported value
$2,035,690,287
% of total 13F portfolios
0%
Share change
+1,883,526
Value change
+$32,888,076
Number of holders
353
Price from insider filings
$23.34
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% $399,180,432 16,892,951 BlackRock, Inc. 31 Mar 2025
STATE STREET CORP 5.2% $126,186,124 6,405,387 STATE STREET CORPORATION 30 Sep 2025
Flynn James E 2.6% $74,033,050 3,133,011 Deerfield Mgmt, L.P. 31 Dec 2024

As of 30 Sep 2025, 353 institutional investors reported holding 103,326,904 shares of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX). This represents 84% of the company’s total 123,180,519 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) together control 59% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 18,216,060 -3.6% 0.01% $358,856,382
VANGUARD GROUP INC 7.1% 8,713,520 -0.6% 0% $171,656,344
STATE STREET CORP 5.2% 6,405,387 +17% 0% $126,186,124
DEERFIELD MANAGEMENT COMPANY, L.P. 4% 4,974,767 +73% 1.5% $98,002,910
RENAISSANCE TECHNOLOGIES LLC 2.9% 3,544,830 +9% 0.09% $69,833,151
Fundsmith LLP 2.7% 3,363,807 +24% 0.33% $66,266,998
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,890,320 +0.82% 0% $56,946,376
AMERICAN CENTURY COMPANIES INC 2.1% 2,528,186 +44% 0.03% $49,805,264
DIMENSIONAL FUND ADVISORS LP 2% 2,458,169 +29% 0.01% $48,424,317
BANK OF AMERICA CORP /DE/ 1.9% 2,291,414 -3.1% 0% $45,140,856
ROYCE & ASSOCIATES LP 1.7% 2,034,965 +29% 0.4% $40,088,810
MORGAN STANLEY 1.5% 1,843,624 -42% 0% $36,319,427
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 1,331,990 -7.3% 0% $26,240,203
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.1% 1,304,774 +6.6% 0.02% $25,704,048
Boston Partners 1% 1,291,059 +0.65% 0.03% $25,576,819
NORTHERN TRUST CORP 1% 1,263,888 -0.88% 0% $24,898,594
Invesco Ltd. 1% 1,233,257 +1.6% 0% $24,295,163
MILLENNIUM MANAGEMENT LLC 0.96% 1,179,182 +174% 0.02% $23,229,885
KENNEDY CAPITAL MANAGEMENT LLC 0.86% 1,060,207 +5% 0.46% $20,886,078
GOLDMAN SACHS GROUP INC 0.82% 1,007,235 -58% 0% $19,842,530
Qube Research & Technologies Ltd 0.67% 821,202 -19% 0.02% $16,177,679
Allianz Asset Management GmbH 0.65% 797,948 -23% 0.02% $15,719,575
Legal & General Group Plc 0.63% 774,104 +17% 0% $15,249,849
RAYMOND JAMES FINANCIAL INC 0.63% 773,330 -8.5% 0% $15,234,600
MACQUARIE GROUP LTD 0.62% 761,740 -16% 0.02% $15,006,000

Institutional Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 812,184 $18,930,270 -$7,066,177 $23.34 28
2025 Q3 103,326,904 $2,035,690,287 +$32,888,076 $19.70 353
2025 Q2 101,339,025 $2,199,165,165 +$74,610,948 $21.70 360
2025 Q1 97,995,812 $2,374,736,976 +$45,703,179 $24.25 365
2024 Q4 97,462,582 $2,034,900,504 +$38,258,566 $20.87 333
2024 Q3 95,380,838 $1,896,646,482 -$35,292,712 $19.88 312
2024 Q2 96,983,113 $1,502,403,827 +$11,987,767 $15.49 269
2024 Q1 96,270,213 $1,534,339,181 +$191,142,132 $15.94 268
2023 Q4 84,453,649 $1,419,515,333 +$62,962,605 $16.81 259
2023 Q3 81,157,485 $948,788,519 -$23,397,502 $11.69 254
2023 Q2 82,218,793 $1,104,943,728 -$95,298,712 $13.44 243
2023 Q1 88,787,264 $1,472,124,820 +$71,196,268 $16.58 256
2022 Q4 84,107,036 $1,564,456,429 -$12,268,287 $18.60 252
2022 Q3 85,176,091 $1,093,105,879 +$187,635,691 $12.83 220
2022 Q2 75,651,199 $530,307,280 +$37,811,777 $7.01 175
2022 Q1 70,838,632 $586,598,135 +$41,265,648 $8.29 181
2021 Q4 66,018,446 $446,683,816 +$3,690,649 $6.77 160
2021 Q3 65,162,167 $345,106,769 -$2,224,745 $5.30 138
2021 Q2 65,482,202 $376,526,274 -$10,746,528 $5.75 137
2021 Q1 67,671,701 $311,885,548 +$10,809,324 $4.61 130
2020 Q4 66,576,359 $222,408,153 -$12,651,094 $3.34 131
2020 Q3 67,907,092 $201,992,589 +$603,491 $2.97 140
2020 Q2 64,719,712 $299,102,386 -$2,974,113 $4.62 138
2020 Q1 65,840,014 $253,546,747 +$11,634,204 $3.85 128
2019 Q4 62,834,633 $235,638,867 -$30,765,313 $3.75 127
2019 Q3 61,617,508 $327,170,529 +$8,126,558 $5.31 117
2019 Q2 61,553,639 $236,256,732 -$4,762,099 $3.84 99
2019 Q1 61,491,932 $313,611,586 +$64,665,968 $5.10 87
2018 Q4 49,136,126 $94,337,873 -$22,145,979 $1.92 85
2018 Q3 51,043,397 $192,937,538 -$11,273,654 $3.78 96
2018 Q2 54,196,334 $169,201,579 +$2,782,969 $3.12 98
2018 Q1 54,723,682 $130,787,787 -$11,120,389 $2.39 97
2017 Q4 56,055,280 $219,183,091 +$80,363,139 $3.91 105
2017 Q3 35,604,156 $89,681,592 +$4,372,606 $2.52 77
2017 Q2 33,946,250 $93,689,694 +$24,746,037 $2.76 68
2017 Q1 25,299,931 $49,329,000 +$4,788,629 $1.95 51
2016 Q4 23,812,013 $25,000,000 +$512,936 $1.05 51
2016 Q3 23,293,467 $25,386,000 -$1,705,125 $1.09 46
2016 Q2 25,351,615 $17,997,000 -$12,327,656 $0.71 57
2016 Q1 36,952,362 $43,231,000 -$15,825,279 $1.17 73
2015 Q4 42,424,296 $103,944,627 -$6,424,568 $2.45 86
2015 Q3 44,724,461 $134,180,687 +$3,442,159 $3.00 88
2015 Q2 43,473,000 $179,861,198 +$18,861,290 $4.13 86
2015 Q1 38,864,127 $168,166,940 +$54,418,957 $4.33 64
2014 Q4 27,360,884 $81,277,000 +$8,330,747 $2.97 49
2014 Q3 23,623,262 $78,388,100 +$8,077,982 $3.32 51
2014 Q2 22,284,591 $56,380,420 +$29,950,485 $2.53 46
2014 Q1 10,454,712 $23,627,120 +$2,788,485 $2.26 36